Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Generic Drugs Leave Rite Aid Feeling Sick

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Generic drugs are good for consumers' wallets, but they aren't good for many other players in the medical industry. Pharmaceutical companies that spend billions of dollars to develop brand name drugs feel the pinch when patents run out, and generics flood the market. Apparently, so do drug stores.

Rite Aid (NYSE: RAD  ) said today that same store sales fell 2% in March from a year earlier, driven by a decline in drug sales. Sales in the pharmacy, which accounts for 67.6% of overall revenue at Rite Aid, fell 4.5%, despite prescriptions rising slightly. This means that lower cost drugs, particularly in the form of generics, have taken a bite out of sales for Rite Aid.

The small silver lining is that the rest of the store is doing quite well. Front-end same-store sales, which is everything outside of the pharmacy, rose 3.8%, helped by a boost in Easter sales.

An industry trend takes hold
This is going to be a challenge for the industry going forward, and will also impact Walgreen's (NASDAQ: WBA  ) and CVS (NYSE: CVS  ) . Walgreens reported a 0.7% rise in same-store sales for March, which was below expectations, showing similar trends as Rite Aid's. The company's same-store pharmacy sales fell 1.5%, not as bad as Rite Aid, but still not a strong sign for the drug business.  

CVS doesn't give the same-store sales data like Rite Aid and Walgreen's but we can assume the trend of more generics and lower pharmacy sales will hold true.

Investors should be careful buying into the declining sales trends at all three companies. As health-care costs have risen, there has been pressure on all parts of the industry to cut costs, and that includes drug stores. That wouldn't be a problem if the stocks were a screaming value, but Walgreen's and CVS both have P/E ratios above 18, which is expensive considering sales trends, and Rite Aid is a risky turnaround story. That's too much for this Fool to pay to get into the drug business.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies, and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 04, 2013, at 11:40 PM, prginww wrote:

    Travis, let me ask you a question: If Rite Aid same store sales rose 3.8% and Walgreens same store sales rose 0.7% which is better? Wouldn't Rite Aid be more valuable than Walgreens. You said that Walgreens reported 0.7% for March same store sales below expectations. The same store prescription sales fell 1.5%. Rite Aid reported an increase of 0.3% of prescription counts compared to last year. Which stock would be a better investment now under these conditions?

  • Report this Comment On April 05, 2013, at 3:52 PM, prginww wrote:

    While I prefer English muffins or bagels, if I do ever decide I want some toast, I will certainly consider Rite Aid.

  • Report this Comment On April 05, 2013, at 8:05 PM, prginww wrote:

    The sales numbers may be down but generics are good for pharmacy profits. The price a generic is sold for is slightly less than its brand name counterpart but the acquisition cost is substantially less. So the profit margin is higher for generic sales. This margin might be decreased though by promotions like $4 generic lists and third party insurer contract prices sucking up the profit.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2347751, ~/Articles/ArticleHandler.aspx, 9/26/2016 3:25:32 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:01 PM
CVS $90.60 Up +0.03 +0.03%
CVS Health CAPS Rating: *****
RAD $8.09 Down -0.03 -0.37%
Rite Aid CAPS Rating: ****
WBA $82.05 Down -0.33 -0.40%
Walgreens Boots Al… CAPS Rating: ****